Q-omics provides the consensus-scored ZBTB7A profile across patient tissues and cancer cell-line models. ZBTB7A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ZBTB7A is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, ZBTB7A RNA expression shows 19,572 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, LIHC, and ACC as cancer lineages where ZBTB7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB7A survival associations across molecular data types. ZBTB7A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB7A RNA expression–survival associations across cancer types. High ZBTB7A expression shows unfavorable associations in LUAD, LGG and MESO, but favorable associations in STAD, KIRC and UCEC. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for ZBTB7A RNA expression.
This table summarizes ZBTB7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB7A shows lower tumor expression in UCEC, BLCA and LUAD and higher tumor expression in LIHC, BRCA and CHOL. The LIHC box plot shows higher ZBTB7A RNA expression in tumor versus normal tissue (log2 FC = +0.845, t-test p < 0.001).
This table shows molecular features associated with ZBTB7A in patient tissues and cancer cell lines. In patient samples, ZBTB7A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
